Skip to main content
Back to Bessemer Venture Partners

Bessemer Venture Partners's Pharmaceutical Portfolio

Browse 7 Pharmaceutical companies funded by Bessemer Venture Partners. See funding amounts, founder contacts, and investment details.

Pharmaceutical Companies
7
Total Funding in Pharmaceutical
$509.8M

Pharmaceutical Portfolio Companies (7)

Export
BiotechnologyPharmaceutical

We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins.

London, United Kingdom
June 2022
$40.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceutical

Florence is a clinical trials platform that connects pharmaceutical companies and study sites to decentralize trials for drug development.

Atlanta, United States
June 2022
$27.0M
Series C

Founder Contacts

30,000+ verified contacts

BiotechnologyPharmaceuticalTherapeutics

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

Newton, United States
May 2022
$2.8M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyPharmaceuticalTherapeutics

Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease.

Lexington, United States
December 2025
$120.0M
Series B

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CarePharmaceuticalTherapeutics

TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.

Waltham, United States
December 2024
$30.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyMedicalPharmaceutical

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Watertown, United States
January 2025
$200.0M
Series A

Founder Contacts

30,000+ verified contacts

BiopharmaBiotechnologyPharmaceutical

Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.

Needham, United States
November 2025
$90.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Explore Bessemer Venture Partners's Full Portfolio

View all companies funded by Bessemer Venture Partners across every industry and funding stage.

View Full Bessemer Venture Partners Portfolio